Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

Parker, Chris; Nilsson, Sten; Heinrich, Daniel; M. O’Sullivan, Joe; D. Fosså, Sophie; Chodacki, Aleš; Wiechno, Paweł; Logue, John; Seke, Mihalj; Widmark, Anders; Clement Johannessen, Dag; Hoskin, Peter; Bottomley, David; E. Coleman, Robert; J. Vogelzang, Nicholas; Gillies O'Bryan-Tear, C.; Garcia‐Vargas, J.; Shan, Minghua; Sartor, Oliver

doi:10.1200/jco.2012.30.15_suppl.lba4512

Public

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

Shared by NobleBlocks on May 20, 2012 • 12:00 AM UTC

Authors:

Chris Parker

Sten Nilsson

Daniel Heinrich

Abstract

LBA4512 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in...

Subject

Medicine

Prostate cancer

Multinational corporation

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!